Dynamic Advisor Solutions LLC Acquires New Shares in Sanofi (NASDAQ:SNY)

Dynamic Advisor Solutions LLC purchased a new stake in Sanofi (NASDAQ:SNY - Free Report) in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 55,837 shares of the company's stock, valued at approximately $3,097,000.

Several other hedge funds also recently modified their holdings of SNY. Invesco Ltd. increased its stake in Sanofi by 3.5% in the fourth quarter. Invesco Ltd. now owns 12,059,283 shares of the company's stock valued at $581,619,000 after purchasing an additional 408,752 shares in the last quarter. Bank of America Corp DE increased its position in Sanofi by 3.8% in the 4th quarter. Bank of America Corp DE now owns 12,017,140 shares of the company's stock valued at $579,587,000 after buying an additional 441,637 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in Sanofi by 88.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 10,843,682 shares of the company's stock worth $522,991,000 after buying an additional 5,091,304 shares during the period. Boston Partners boosted its holdings in Sanofi by 86.4% in the fourth quarter. Boston Partners now owns 5,396,531 shares of the company's stock worth $260,607,000 after acquiring an additional 2,501,073 shares in the last quarter. Finally, Franklin Resources Inc. grew its stake in Sanofi by 10.8% in the fourth quarter. Franklin Resources Inc. now owns 3,776,982 shares of the company's stock valued at $182,164,000 after acquiring an additional 369,530 shares during the period. Institutional investors and hedge funds own 14.04% of the company's stock.

Sanofi Price Performance

Shares of SNY traded down $0.26 during midday trading on Monday, hitting $49.41. 1,945,610 shares of the company traded hands, compared to its average volume of 2,380,133. Sanofi has a one year low of $45.80 and a one year high of $60.12. The firm has a market cap of $121.18 billion, a P/E ratio of 19.84, a PEG ratio of 1.01 and a beta of 0.50. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14. The stock has a 50-day moving average of $51.49 and a 200-day moving average of $52.06.

Sanofi (NASDAQ:SNY - Get Free Report) last announced its earnings results on Thursday, April 24th. The company reported $0.94 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.90 by $0.04. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. The business had revenue of $10.41 billion during the quarter, compared to analyst estimates of $9.79 billion. During the same period in the previous year, the business posted $1.78 earnings per share. Sanofi's revenue for the quarter was down 11.0% on a year-over-year basis. As a group, sell-side analysts predict that Sanofi will post 4.36 EPS for the current fiscal year.

Sanofi Increases Dividend

The firm also recently disclosed an annual dividend, which was paid on Thursday, June 12th. Stockholders of record on Friday, May 9th were given a $2.0369 dividend. This is a positive change from Sanofi's previous annual dividend of $1.48. This represents a dividend yield of 3.1%. The ex-dividend date of this dividend was Friday, May 9th. Sanofi's dividend payout ratio (DPR) is currently 56.79%.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. BNP Paribas started coverage on Sanofi in a research report on Tuesday, April 15th. They set an "outperform" rating and a $65.00 target price on the stock. The Goldman Sachs Group began coverage on shares of Sanofi in a research note on Friday, March 21st. They issued a "neutral" rating and a $65.00 price objective on the stock. Guggenheim reissued a "buy" rating on shares of Sanofi in a research report on Tuesday, June 3rd. Morgan Stanley set a $56.00 target price on shares of Sanofi in a report on Monday, June 2nd. Finally, Hsbc Global Res upgraded Sanofi to a "strong-buy" rating in a research note on Monday, April 28th. Three analysts have rated the stock with a hold rating, three have issued a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, Sanofi has a consensus rating of "Buy" and a consensus price target of $61.50.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.